MannKind (MNKD) Stock

Company plans to meet with FDA regarding potential sNDA submission in 1H 2025 Call planned today at 8:30 a.m. (ET) to discuss company's diabetes program progression DANBURY, Conn.

India has the 2 nd highest burden of diabetes worldwide CDSCO decision follows existing approvals in the U.S.A. and Brazil MannKind expects to ship product for Cipla Ltd.

MannKind (MNKD) came out with quarterly earnings of $0.04 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.02 per share a year ago.

DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

Met primary objective demonstrating nintedanib DPI was safe and well tolerated Participants did not experience adverse events typically reported with oral nintedanib Expect to meet with the FDA in 1H 2025 to advance MNKD-201 into the next phase of development DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

MannKind (MNKD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

MannKind (MNKD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

MannKind's stock has surged 73%, driven by its 9% royalty stake in United Therapeutics' Tyvaso DPI, which excels in the PAH market. In Q2 2024, MannKind's revenues rose 49% year-over-year to $72 million, largely due to Tyvaso DPI royalties and manufacturing income. MannKind is advancing a promising pipeline, including MNKD 101 and Nintedanib DPI, aimed at addressing unmet needs in orphan lung diseases.